Navigation Links
Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
Date:7/25/2013

MILWAUKEE, July 25, 2013 /PRNewswire/ -- Promentis Pharmaceuticals, Inc., a private, emerging pharmaceutical company focused on developing a therapeutic platform for neuropsychiatric disorders, with an initial emphasis on creating drugs for the treatment of schizophrenia, announced today that Chad Beyer, Ph.D., MBA, has been appointed as President and Chief Executive Officer.

With nearly 20 years experience, Dr. Beyer's career encompasses research, discovery and the business development of medications intended for central nervous system (CNS) and neurological disorders.  As an entrepreneur, Dr. Beyer has founded a biotech consulting company and helped launch a specialty pharmaceutical company focused on developing treatments for acute pain conditions.

Klaus Veltinger, M.D., Ph.D., and chairman of Promentis' board of directors, stated, "We are thrilled to have Chad on board, he brings exceptional development experience to a well-established program that has already made considerable progress."   

Given Dr. Beyer's significant and extremely relevant experience in neuroscience, we're confident his abilities will have a direct and marked impact on Promentis' growth efforts."

For more than a decade, Dr. Beyer worked in the Discovery Neuroscience group at Wyeth Pharmaceuticals, where he held multiple positions of increasing responsibility, including Head of Neurochemistry.  During his time at Wyeth, he also led several drug discovery teams and managed a group of scientists that contributed to the submission of more than 30 INDs and generated supporting data for the commercialization and life-cycle management of Effexor® and Pristiq®, two of the company's blockbuster medications.

"Promentis is aggressively moving innovative science and novel treatment strategies closer to the millions of people suffering with CNS diseases," said Dr. Beyer.  "I am honored to join this unique team and to lead the company's drug discovery efforts closer to patients and their families."

Shortly after beginning his research career at the National Institutes of Health (NIH) in NIDA's Addiction Research Center, Dr. Beyer earned his Ph.D. in Pharmacology from Louisiana State University Medical Center and an MBA from the Rutgers School of Business.  He has authored more than 70 manuscripts, been granted three patents, is an editor of Next Generation Antidepressants, a psychiatry review book, and is co-founder of the journal Technology Transfer & Entrepreneurship.  Dr. Beyer also serves as an adjunct faculty member at Thomas Jefferson University where he teaches Bioventure Management.

About Promentis Pharmaceuticals, Inc:
Promentis Pharmaceuticals, Inc. was founded in 2007 and is a private, emerging pharmaceutical company focused on developing unique compounds aimed at modifying brain chemistry for the treatment of schizophrenia and other central nervous system disorders.  Support for Promentis' drug discovery and development programs, in part, is provided by recent grants from the National Institute of Mental Health (NIMH) and the Michael J. Fox Foundation.  Additional information can be found at www.promentispharma.com.

Media Contact:
Tiberend Strategic Advisors, Inc.
(212) 375-2694
Andrew Mielach
amielach@tiberend.com


'/>"/>
SOURCE Promentis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
9. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
10. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
11. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
Breaking Medicine News(10 mins):